RC
PCVX icon

Renaissance Capital’s Vaxcyte PCVX Stock Holding History

Renaissance Capital’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-23,688
Closed -$888K – 83
2023
Q1 		$888K Sell
23,688
-2,548
-10% -$108K 0.66% 41
2022
Q4 		$1.26M Buy
+26,236
New +$1.03M 0.98% 27

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Capital's PCVX Position: Q2 2023 in Review

Renaissance Capital sold out of Vaxcyte (PCVX) in Q2 2023, closing a stake of 23,688 shares — an estimated $888K sold.

Renaissance Capital first reported a position in PCVX in Q4 2022 and held it in 2 quarters. The position peaked at $1.26M in Q4 2022. 197 funds tracked by Wall St. Rank hold PCVX as of Q2 2023.

  • Renaissance Capital reported no remaining Vaxcyte position as of Q2 2023 after selling out during the quarter.
  • Renaissance Capital sold 23,688 Vaxcyte shares in Q2 2023, an estimated $888K.
  • Renaissance Capital first reported a position in Vaxcyte in Q4 2022 and held it in 2 quarters.
  • Renaissance Capital's Vaxcyte position peaked at $1.26M in Q4 2022.
  • 197 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2023.

Based on Renaissance Capital's 13F filing for Q2 2023, filed 17 Jul 2023.